Drugs / ELVN-002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06328738 | May 2024 → Jan 2027 expected | HER2 positive breast carcinoma, colorectal cancer | Enliven Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05650879 | Mar 2023 → Jul 2026 overdue | HER2 positive breast carcinoma, lung cancer | Enliven Therapeutics | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-19 | Enliven Therapeutics | Results Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates enliventherapeutics.com ↗
Investigator reported responses (including unconfirmed) in both HER2+ and HER2 mutant tumors, including in patients who have progressed on Enhertu and patients with brain metastases, at doses that have been well tolerated. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-03-19 | Enliven Therapeutics | Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates enliventherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELVN-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650879 ↗ |
| Route | Oral | “ELVN-002 is an oral capsule.” NCT05650879 ↗ |